Myeloma Associated studies

Planned Trials

Short name EMN39
Title A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant Conditions
Phase Phase 3
Therapy Linvoseltamab vs SOC
Objectives Efficacy
Population Transplant ineligible NDMM
Eligibility Eligibility criteria in protocol
Status Not yet open
Information clinicaltrials.gov/study/ NCT06932562
Participants EMC, Rotterdam
Short name QUINTESSENTIAL-2
Title A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma 
Phase Phase 3
Therapy BMS-986393 Versus Standard Regimens
Objectives Efficacy (PFS)
Population RRMM: Prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible)
Eligibility Eligibility criteria in protocol
Status Not yet open
Information clinicaltrials.gov/study/NCT06615479
Participants UMCG, Groningen; UMCU, Utrecht; UMCN, Nijmegen; MUMC, Maastricht, UAMC, Amsterdam

Open Trials

Short name NCT05652335
Title Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Phase Phase 1
Therapy JNJ-79635322, a Trispecific Antibody
Objectives Safety and RP2D, part 1; dose escalation, part 2 dose expansion
Population RRMM and previously treated AL amyloidosis , as described in the protocol
Eligibility Eligibility criteria in protocol
Status Open
Information clinicaltrials.gov/study/NCT05652335
Participants UMCU, Utrecht; UMCG, Groningen; AUMC, Amsterdam
Short name SUCCESSOR-2
Title A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase Phase 3
Therapy MeziKD vs Kd
Objectives Efficacy (PFS)
Population Prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible)
Eligibility Eligibility criteria in protocol
Status Open
Information clinicaltrials.gov/study/ NCT05552976
Participants MST, Twente; Amphia ZH, Breda
Short name NCT05201781
Title A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Phase Phase 4, Data collection
Objectives Collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Population Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
Eligibility Eligibility criteria in protocol
Status Open
Information clinicaltrials.gov/study/NCT05201781
Participants UAMC, Amsterdam; UMCG, Groningen
Short name MagnetisMM-32
Title A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide
Phase Phase 3
Therapy Elranatamab vs SOC (Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd))
Objectives Efficacy (oa PFS)
Population 1 to 4 PL,  including anti-CD38 antibody and prior lenalidomide.
Eligibility Eligibility criteria in protocol
Status Open
Information clinicaltrials.gov/study/NCT06152575
Participants MUMC, Maasstricht; ASZ, Dordrecht; EMC, Rotterdam
Short name ITUMM
Title Telemonitoring Among Patients With Multiple Myeloma
Phase Phase 3
Therapy Telemonitoring vs SOC monitoring
Objectives

Impact on Correct Drug Use, Complications and Quality of Life
using telemonitoring (MM e-coach) vs standard MM care. Impact on Correct Drug Use, Complications and Quality of Life

Population Multiple Myeloma
Eligibility Eligibility criteria in protocol
Status Open
Information clinicaltrials.gov/study/NCT05964270
Participants Zwolle, Overijssel, Netherlands
Short name iMMagine-3
Title A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)
Phase Phase 3
Therapy Anitocabtagene Autoleucel vs SoC
Objectives Efficacy (PFS)
Population Relapsed/ Refractory Multiple Myeloma
Eligibility Eligibility criteria in protocol
Status Open
Information clinicaltrials.gov/study/NCT06413498
Participants UMCG, Groningen
Short name EMN40
Title A Phase 2 Trial of Teclistamab in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis
Phase Phase 2
Therapy Teclistamab monotherapy, duration 6 months
Objectives Hematological CR rate after 3 cycles
Population Relapsed patients with AL amyloidosis
Eligibility Previously treated with an alkylating agent and/or a proteasome inhibitor and dexamethasone and/or daratumumab and/or IMID. Measurable hematological disease (dFLC > 20), eGFR > 20 ml/min
Status Open 15 June 2025
Information EMN40 - European Myeloma Network
Participants UMC Utrecht
Short name EMN28/Cartitude-6/EM-agine
Title A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
Phase Phase 3
Therapy Dara-VRD/HDM/ASCT vs DaraVRD/CAR-T
Objectives Efficacy (PFS) en safety
Population NDMM TE patients
Eligibility NDMM transplant eligible
Status Open
Information EMN 33 - European Myeloma Network 
Participants EMC, Amsterdam UMC, UMCU, UMCG, Radboud UMC
Short name EMN33/ TAURUS
Title Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants with Previously Untreated Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUS
Phase Phase 2
Therapy Dara-VRD, HDM/ASCT. Gebuik makend van bloodbased MRD
Objectives Efficacy (PFS) en safety
Population NDMM TE patients
Eligibility NDMM transplant eligible
Status Open
Information EMN 33 - European Myeloma Network
Participants Many hospitals in the Netherlands, inform at a centre near you
Short name EMN30/ MAJESTEC-4
Title Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation – The Majestec-4 study
Phase Fase 3, onderhoud
Therapy Teclistamab/ Lenalidomide vs. Teclistamab vs. Lenalidomide
Objectives Efficacy (PFS) en safety
Population NDMM TE patients
Eligibility NDMM transplant eligible
Status Open
Information EMN30 - European Myeloma Network
Participants EMC, Amsterdam UMC, UMCG, ASZ, and other centres, inform at a centre near you
Short name MAGNETISMM-6
Title Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone In Transplant-ineligible Participants With Newly-diagnosed Multiple Myeloma
Phase Fase 3
Therapy Elranatamab + daratumumab + lenalidomide (EDR) versus Daratumumab + lenalidomide + dexamethasone (DRd)
Objectives Efficacy (PFS) en safety
Population NDMM TIE patients
Eligibility NDMM transplant ineligible
Status Open
Information https://clinicaltrials.gov/study/NCT05623020
Participants VieCuri, ASZ
Short name Excaliber-maintenance
Title A Randomized, 2-arm, Phase 3 Study Of Elranatamab (Pf-06863135) Versus Lenalidomide In Patients With Newly Diagnosed Multiple Myeloma After Undergoing Autologous Stem-cell Transplantation
Phase Fase 3, onderhoud
Therapy Iber vs len onderhoud na autoPSCT
Objectives Efficacy (PFS) en safety
Population NDMM TE patients, onderhoud
Eligibility NDMM transplant eligible
Status Open
Information https://clinicaltrials.gov/study/NCT05317416
Participants ASZ Dordrecht
Short name MAJESTEC-7
Title A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
Phase Fase 3
Therapy Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR)
Objectives Efficacy (PFS) en safety
Population NDMM TE patients
Eligibility NDMM transplant eligible
Status Open
Information https://clinicaltrials.gov/study/NCT05552222
Participants Amsterdam UMC, Antonius, Reinier de Graaf ZH Delft, Gelre ZH, Apeldoorn, St Antonius ZH, Nieuwegein, Zuiderland Medisch centrum, Sittard-Geleen
Short name MagnestisMM-7
Title A Randomized, 2-Arm, Phase 3 Study of Elranatamab (PF-06863135) Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
Phase Phase 3
Therapy Elranatamab Versus Lenalidomide maintenance
Objectives Safety and Efficacy (part 1, safety lead-in, part 2 randomized)
Population

Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MRD measured by NGS (central lab)

Eligibility Eligibility criteria in protocol
Status Open in HAGAZH
Information https://clinicaltrials.gov/ct2/show/NCT05317416
Participants

Isala ZH, Zwolle; MUMC, Maastricht

Short name MagnestisMM-5
Title

A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Phase Phase 3
Therapy Elranatamab Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone
Objectives Safety and Efficacy (part 1, safety lead-in, part 2 randomized)
Population

Only open for part 2
Part 2:  >1 PL, niet dara-refractair

Eligibility Eligibility criteria in protocol
Status Not open yet
Reference https://clinicaltrials.gov/ct2/show/NCT05020236
Participants

MUMC / ErasmusMC

 

Short name MonumenTAL-6
Title A phase 3 randomized study comparing talquetamab in combination with pomalidomide (Tal-P), talquetamab in combination with teclistamab (Tal-Tec) and investigator’s choice of either elotuzumab, pomalidomide and dexamethasone (EPd) or pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory myeloma who have received 1 to4 prior lines of therapy including an anti-CD38 antibody and lenalidomide
Phase Phase 3
Therapy Talquetamab+pomalidomide versus Talquetamab+teclistamab versus elotuzumab+pomalidomide (EPd) or pomalidomide+bortezomib (PVd)
Objectives Efficacy (PFS) en safety
Population RRMM
Eligibility RRMM, 1-4 eerdere lijnen (behandeld met lenalidomide en antiCD38 antistof)
Status Open
Reference https://clinicaltrials.gov/study/NCT06208150
Participants

Flevoziekenhuis, Almere; HagaZH, Den Haag; Catherina ZH, Eindhoven; AntoniusZH, Nieuwegein; IsalaZH, Zwolle

 

Closed Trials

EMN29
Majestec-3
Majestec-9
EXCALIBER
Trimm-2 studie
Majestec-1
Monumental-1
Monumental-2
Monumental-3
Celgene CC-220-MM-001
ICON
LAVA
Gen3014-01
CA058-002
EMN34/ ERASMM
79635322MMY1001
EMN22
LYNX

Up